Drugs / CD40.RBDv
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07605520 | May 2026 → May 2028 expected | — | ANRS, Emerging Infectious Diseases | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06255626 | May 2024 → Sep 2025 overdue | COVID-19 | ANRS, Emerging Infectious Diseases | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD40.RBDv | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07605520 ↗ |
| Modality | Vaccine | “CD40.RBDv vaccine” NCT06255626 ↗ |
| Route | Subcutaneous | “SC injection of HD CD40.RBDv vaccine adjuvanted” NCT06255626 ↗ |